Partial Alpha 1 Antitrypsin Deficiency (Pi MZ)

Introduction

This leaflet is written for people who are found to be carriers of alpha 1 antitrypsin deficiency $(\alpha 1AD)$.

What is $\alpha 1$ antitrypsin ($\alpha 1AT$)

α1AT is a chemical made in the liver that circulates in your bloodstream.

Why is α 1AT important?

 α 1AT protects lung tissue from an enzyme (elastase) released by white blood cells. Elastase fights infection in the lungs. However if not tightly controlled by α 1AT, elastase can attack healthy lung tissue.

What is α1AD?

Individuals with $\alpha 1AD$ have very low levels of $\alpha 1AT$ in their bloodstream. Carriers have levels which are low but much closer to normal.

How common is being a carrier of α 1AD?

Around 1 in 10 people are carriers for the S or Z variant. 4% (1 in 25) of the Northern European population carry Z and 6% (1 in 17) carry S.

What are the effects of being a carrier of α 1AD?

All the information in studies carried out throughout the world indicates that having partial deficiency (Pi MZ) is not associated with any specific tendency to develop severe health problems. There has been some information to suggest there may be a very slight increased tendency to developing liver cirrhosis. There may be a possible slight relationship to the development of asthma, but these people are certainly no more likely to develop emphysema than any other healthy person who smokes.

What causes α1AD?

Our ability to make $\alpha 1AT$ is inherited through genes passes on by both parents. One of these genes is known as Protease Inhibitor (Pi). It is this gene that makes the $\alpha 1AT$.

How is it inherited?

We all have two Pi genes. We inherited one gene from our mother and the other gene from our father. When a couple has a child they each pass on one of their Pi genes.

What are the different genetic types?

There are more than 100 different variants of the Pi gene. Most variants result in normal levels of $\alpha 1AT$ in the blood, but some result in reduced levels or no $\alpha 1AT$. The most common variants are called M, S and Z.

Most people have two copies of type M variant (written as Pi MM) and have normal levels of $\alpha 1AT$ in the bloodstream.

Author: Rebecca Bray Issue date: November 2023 Review date: November 2026

Information for Patients

PiZZ

Type Z results in low levels of α1AT in the bloodstream. Someone with two Z variants (PiZZ) has α1AD

What do carriers of α 1AT need to do to look after their health?

- 1. Avoid smoking and passive smoking. Smoking attracts white blood cells to the lungs and speeds up the development of lung disease. Other lung irritants e.g. dust particles and certain chemicals, should be avoided where possible
- 2. Ask family members or partners to get tested for α1AD

The reason for doing this is chance. Everyone has a 3 to 6 chance in 100 of marrying or partnering another person with a similar partial deficiency, as it is quite common in the general population.

If we identify such a partner this has very important implications for their present or future children.

For instance, if a Pi Z deficient patient marries a partially deficient (Pi MZ) person, 1 in 2 of their children is likely to have severe deficiency (Pi Z) as well as their parent (the patient we originally found). If on the other hand a person with partial alpha 1 antitrypsin deficiency (Pi MZ) marries another patient with partial deficiency, 1 in 4 of their children, again by chance, should develop severe deficiency of the Pi Z type.

It is the detection of these children that is the most important factor. By understanding that they have the deficiency, they can be advised with the help of their parents never to take up smoking and, if so, it is highly unlikely that they will develop severe emphysema. We know that prompt treatment of all chest problems is important in retaining the health of these children and also they require advice on which jobs would or would not be suitable for someone with their tendency to develop lung disease.

In other words, it is the aim of doing these tests to prevent ill health in children and grandchildren, nephews and nieces before it really starts.


Will my children have α 1AD if I am a carrier?

If your partner is not a carrier you will not have a child with α1AD. Your children will each have a 50% chance of being a carrier. If your partner is also a carrier (Pi MZ) there will be three possible outcomes in each pregnancy.

- 1. 1 in 4 (25%) chance you will both pass on the Z variant so your child will have α1AD
- 2. 1 in 2 (50%) chance one of you will pass the Z type and the other will pass the normal variant so the child will be a carrier of α1AD
- 3. 1 in 4 (25%) chance neither of you will pass on the Z variant so your child will not be a carrier of α1AD

PI23/1846/04 Leaflet title: Partial Alpha1 Antitrypsin Deficiency

Issu e date: November 2023 Review date: November 2026 Author: Rebecca Bray



Further information

Alpha-1 UK Support Group Email: info@alpha1.org.uk Web: www.alpha1.org.uk

Alpha-1 Awareness UK

www.facebook.com/groups/alpha1awareness.uk

next appointment.

PI23/1846/04 Leaflet title: Partial Alpha1 Antitrypsin Deficiency

Author: Rebecca Bray Issu e date: November 2023 Review date: November 2026

Information for Patients		
	 	

*With thanks to the Clinical Genetics Unit, Birmingham Women's NHS Foundation Trust

If you need more advice about alpha 1 antitrypsin deficiency please contact:

Alpha-1 Specialist NHS Service/ADAPT Project Lung Function and Sleep Department Level 0, Outpatients Area 3
Queen Elizabeth Hospital Birmingham
Mindelsohn Way, Edgbaston
Birmingham B15 2GW

Tel: 0121 371 3885

Email: ADAPT@uhb.nhs.uk

Website: www.uhb.nhs.uk/services/respiratory-medicine/alpha-1-antitrypsin-deficiency-aatd.htm

If you require this information in another format, such as a different language, large print, braille or audio version please ask a member of staff or email patientexperience@uhb.nhs.uk.

Pl23/1846/04 Leaflet title: Partial Alpha1 Antitrypsin Deficiency Page 4 of 4

Author: Rebecca Bray Issue date: November 2023 Review date: November 2026